Long-acting glucagon-like peptide-1 derivative, and preparation method therefor and use thereof

By introducing branched structure modifications into the GLP-1 polypeptide backbone, a long-acting glucagon-like peptide-1 derivative was formed, which solved the problem of instability of GLP-1 drugs in vivo, achieved extended half-life and enhanced activity, and achieved a therapeutic effect similar to semaglutide.

WO2024234320A1PCT designated stage expired Publication Date: 2024-11-21NANJING ZHIHE MEDICINE TECH CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/094658
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing GLP-1 drugs are unstable in vivo, are easily degraded by DPP-IV, have short half-lives, and are difficult to achieve long-term effects. Furthermore, existing side chain modification methods may affect the affinity and activity of peptides.

Method used

By introducing specific branched structure modifications into the GLP-1 peptide backbone, including amide bond linkages of amino acid side chains, and synthesizing branched fragments and peptide chains using solid-phase or liquid-phase methods, long-acting glucagon-like peptide-1 derivatives are formed. Combined with appropriate stereoisomers and mixture forms, the stability and affinity of the drug are improved.

Benefits of technology

It significantly prolonged the drug's half-life, enhanced its agonistic activity with the GLP-1 receptor, and achieved better pharmacokinetic effects. In particular, through changes in the branched chain structure, it prolonged the half-life and maintained or improved the peptide's activity, achieving therapeutic effects similar to or better than semaglutide.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023094658_21112024_PF_FP_ABST
    Figure CN2023094658_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a long-acting glucagon-like peptide-1 derivative, and a preparation method therefor and a use thereof. The long-acting glucagon-like peptide derivative is shown in formula (I), and X1 in a main chain has and only has one amino group of a side chain thereof connected to an acyl group of a branched chain shown in formula (II) to form amide. Also disclosed is a use of the long-acting glucagon-like peptide-1 derivative or a salt thereof and a pharmaceutical preparation thereof in treatment and / or prevention of type II diabetes, impaired glucose tolerance, type I diabetes, obesity-related diseases, metabolic syndrome, non-alcoholic steatohepatitis, non-alcoholic fatty liver diseases, neurodegenerative diseases and the like.
Need to check novelty before this filing date? Find Prior Art

Description

A long-acting glucagon-like peptide-1 derivative and its preparation method and use Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a long-acting glucagon-like peptide-1 derivative and a preparation method and use thereof. Background Art

[0002] Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by human intestinal L cells. It promotes insulin secretion and inhibits glucagon secretion, lowering blood glucose levels and is used to treat type 2 diabetes and obesity. However, native GLP-1 is unstable in vivo and is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV), with a half-life of less than 2 minutes. The function of GLP-1 is mediated by the GLP-1 receptor (GLP-1R). The GLP-1R is widely distributed in multiple tissues and organs throughout the body, including the pancreas, liver, kidneys, and brain. The physiological effects and mechanisms of hypoglycemic effects of GLP-1 receptor agonists or drugs include bidirectional regulation of the secretory function of pancreatic α- and β-cells, promoting β-cell differentiation and proliferation, inhibiting β-cell apoptosis, and reducing inflammatory cell infiltration, thereby improving β-cell function, increasing β-cell sensitivity to glucose, promoting glucose-dependent insulin secretion, and inhibiting glucagon release. The beneficial physiological effects and mechanisms of GLP-1 receptor agonists or drugs on the cardiovascular system include reducing oxidative stress, promoting NO release, improving endothelial function, inhibiting inflammatory responses, reducing left ventricular remodeling, delaying AS progression, lowering systolic blood pressure and pulmonary capillary wedge pressure, increasing myocardial salvage rate after myocardial infarction, increasing autophagy, reducing myocardial damage, regulating intracellular calcium concentrations in myocardial cells, preventing myocardial cell apoptosis, and ameliorating metabolic factors and age-induced myocardial fibrosis, thereby improving cardiovascular system function and reducing the incidence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. The physiological effects and mechanisms of GLP-1 receptor agonists or drugs for weight loss are as follows: GLP-1 can be synthesized in the central nervous system, and GLP-1 receptors are widely distributed in the brain. This means that GLP-1 is both a gastrointestinal hormone and a brain neuropeptide. Its central nervous system-mediated effects inhibit gastrointestinal secretion and motility (especially delaying gastric emptying), increase satiety, and affect food intake, thereby achieving the dual goals of lowering blood sugar and reducing weight. The physiological effect and mechanism of GLP-1 receptor agonists or drugs in protecting the liver is that GLP-1 receptors are present in hepatocytes. GLP-1 receptor agonists or drugs can activate the liver's GLP-1R, directly regulating liver lipid metabolism, oxidative stress, and inflammatory responses caused by endoplasmic reticulum stress, reducing the liver's visceral fat content, thereby protecting liver cells and further preventing and delaying the occurrence and development of non-alcoholic fatty liver disease. The physiological effect and mechanism of GLP-1 receptor agonists or drugs in strengthening the brain is that they can activate the GLP-1R in the brain, enhance nerve growth factor-mediated neuronal differentiation, stimulate synaptic growth, reduce glucose transport across the blood-brain barrier, promote normalization of dopamine metabolism in the brain, and increase dopamine neurons.

[0003] Semaglutide, also known as semaglutide in Chinese and Semaglutide in English, is a novel long-acting glucagon-like peptide-1 (GLP-1) analog developed and produced by Novo Nordisk of Denmark. It has clinical benefits such as lowering blood sugar, reducing weight, and protecting cardiovascular health. It may also have therapeutic implications for NASH (non-alcoholic fatty liver disease) and Alzheimer's disease (AD). Semaglutide for injection, Ozempic, for lowering blood sugar and reducing cardiovascular risk, semaglutide for oral administration, Rybelsus, for lowering blood sugar, and semaglutide for injection, Wegovy, for weight loss, have been approved for marketing in various countries around the world. After the Lys side chain of semaglutide is modified with AEEA (Chinese name 2-(2-(2-aminoethoxy)ethoxy)acetic acid), Glu and octadecanedicarboxylic acid, its hydrophilicity is greatly improved and its binding ability with albumin is enhanced; at the same time, after the Ala at the second position of the N-terminus is mutated to Aib, it effectively avoids inactivation by DPP-IV enzymatic hydrolysis. The average half-life of semaglutide Ozempic for injection reaches 6.3 days, and patients only need to be injected once a week.

[0004] Jesper Lau et al. (Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide, J. Med. Chem, 2015, 58: 7370-7380) and Lotte Bjerre Knudsen and Jesper Lau et al. (The Discovery and Development of Liraglutide and Semaglutide, Front Endocrinol., 2019, 10: 155) elaborated on the research process of different modifications to the side chains of polypeptides to achieve the purpose of extending the half-life while maintaining the affinity of the polypeptide. The contents of semaglutide and other GLP-1 derivatives are respectively reflected in Chinese patent CN101133082B and world patent WO2006 / 097537 A2. Jinhua Zhang et al. (Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates, Bioorg. Med. Chem., 2021, 44: 116291) and Jing Ha et al. (Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity, Biochem. Pharmacol., 2013, 86: 297–308) have tried new side chain modification methods.

[0005] GLP-1 drugs, with their unique target advantages, have become a hot topic in research and development. Approximately 291 GLP-1 drugs are currently under development at various stages worldwide. Extending half-life while simultaneously improving or maintaining peptide affinity is a major challenge in drug development and a persistent goal for researchers. Statistics show that the global average growth rate of diabetes prevalence is 51%, with China boasting 116.4 million people with diabetes, the highest number in the world. This large patient population underscores the robust clinical demand for GLP-1 drugs in the domestic market.

[0006] Summary of the Invention

[0007] The present invention provides a long-acting glucagon-like peptide-1 derivative or a pharmaceutically acceptable salt thereof. The long-acting glucagon-like peptide-1 derivative is represented by formula (I), wherein X1 in the main chain has only one amino group of its side chain connected to the acyl group of the side chain represented by formula (II) to form an amide: 7 H-Aib-E- 10 GTFTSDVSSY- 20 LEGQA- 25 A-X1-EFI- 30 AWLV-X2- 35 GRG (I)

[0008] Wherein, Aib is aminoisobutyric acid, X1 is selected from K amino acid, X2 is selected from K or R amino acid, X1 has only one amino group on its side chain connected to the acyl group of the branch shown in formula (II) to form an amide; n is 7 or 8.

[0009] For ease of identification and presentation, the amino acid sequence uses the method of marking the amino acid position in the upper left corner of some amino acids. The position number is derived from and corresponds to the position of the human GLP-1 (7-37) amino acid sequence.

[0010] In one embodiment of the present invention, the long-acting glucagon-like peptide-1 derivative is represented by the following formula (III):

[0011] Formula (III) is expressed as a polypeptide compound (1): X1 is K, the amino acid side chain ε amino group thereof is connected to the branched structure in the form of an amide bond, X2 is R, and n is 7.

[0012] In one embodiment of the present invention, the long-acting glucagon-like peptide-1 derivative is represented by the following formula (IV):

[0013] Formula (IV) is expressed as polypeptide compound (2): X1 is K, the amino acid side chain ε amino group thereof is connected to the branched structure in the form of an amide bond, X2 is R, and n is 8.

[0014] In one embodiment of the present invention, the long-acting glucagon-like peptide-1 derivative is of the following formula (V):

[0015] Formula (V) is expressed as a polypeptide compound (3): X1 is K, the ε amino group of the amino acid side chain is connected to the branched structure in the form of an amide bond, X2 is K, and n is 7;

[0016] In one embodiment of the present invention, the long-acting glucagon-like peptide-1 derivative is the following formula (VI):

[0017] Formula (VI) is expressed as a polypeptide compound (4): X1 is K, the amino acid side chain ε amino group thereof is connected to the branched structure in the form of an amide bond, X2 is K, and n is 8.

[0018] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, and (L)-isomers, as well as racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. All of these isomers and their mixtures are included within the scope of the present invention. In an embodiment of the present invention, as a preferred embodiment of the present invention, the amino acids in the polypeptide compound are preferably L-amino acids.

[0019] The amino acids described in this article are all abbreviated using the international standard single-letter or three-letter abbreviations.

[0020] In another aspect, the present invention provides a method for preparing the long-acting glucagon-like peptide-1 derivative, the method comprising the following step A:

[0021] 1) Synthesis of branched fragments by solid-phase or liquid-phase methods;

[0022] 2) Solid phase synthesis of peptide chains;

[0023] 3) coupling the branched fragment to the peptide resin;

[0024] 4) Cleavage and removal of the protecting group and the resin mounting to obtain a long-acting glucagon-like peptide-1 derivative.

[0025] The present invention provides another method for preparing the long-acting glucagon-like peptide-1 derivative, which comprises the following step B:

[0026] 1) Solid phase synthesis of peptide chains;

[0027] 2) The side chain modules are coupled to the peptide resin one by one using the solid phase method;

[0028] 3) Cleavage and removal of the protecting group and the resin mounting to obtain a long-acting glucagon-like peptide-1 derivative.

[0029] In some embodiments, the scheme for synthesizing the branched fragment in step A is as follows:

[0030] The mono-protected long fatty diacids are linked sequentially or in reverse order according to the structural order of the branched segments of the present invention, and finally the active groups that need to be bound to the peptide chain are removed. This step can be performed by solid phase synthesis of the polypeptide or by liquid phase synthesis.

[0031] The specific implementation steps are:

[0032] 3,6-dioxa-octanedioic acid (structure shown below) monoprotected with benzyl ester is condensed and coupled with 3,6-dioxa-1,8-octanediamine (structure shown below) monoprotected with Boc (tert-butyloxycarbonyl) under weak organic base conditions, and the Boc protection is removed by TFA; Fmoc-Glu-OtBu is condensed and coupled with the product of the previous step, and the Fmoc protection is removed by Pip / DMF solution or other alkaline solution; a long fatty diacid monoprotected with tBu group is condensed and coupled to the amino position of E; finally, the benzyl ester is removed by hydrogen hydrolysis under the action of palladium carbon catalysis, exposing the carboxyl group of B2 that needs to be bound to the peptide chain.

[0033] In some embodiments, the scheme for synthesizing the main chain in step A is as follows:

[0034] According to the amino acid sequence of the molecular structure of the present invention, Fmoc-protected amino acids are sequentially coupled to a solid-phase synthesis resin, and the Fmoc protection is removed by using a Pip / DMF solution or other alkaline solution, and the cycle is repeated until all the main chain amino acids are completed; the α-amino group of the last amino acid His is protected by a Boc group; the Lys of the side chain fragment to be connected is protected by Alloc (optionally, the raw material Fmoc-Lys(Alloc)-OH is used); and the peptide chain is synthesized using a resin that can construct carboxylic acid-type amino acids, such as CTC resin, Wang resin, HMPA-MBHA resin, HMBA-AM resin, hydroxymethyl resin, RinkAcid resin, etc.

[0035] In some embodiments, the scheme for coupling the side chain to the peptide chain in step A is as follows:

[0036] The side chain protection of the specific modification site of the peptide resin is removed; the branched fragment is coupled to the peptide resin; finally, the protecting group and the resin are cleaved and removed to obtain a long-acting glucagon-like peptide-1 derivative.

[0037] The specific implementation steps are:

[0038] The Alloc protection of X1 (Lys) is removed using tetrakis(triphenylphosphine)palladium and PhSiH3; the side chain fragment is condensed and coupled to the peptide resin; the Fmoc protection is removed using a Pip / DMF solution or other alkaline solution; a cleavage solution is prepared in the ratio (TFA:EDT:TIS:H2O=95:2:2:1), and the fully protected peptide resin is added to the cleavage solution to cleave it from the resin and remove the side chain. TFA is removed by vacuum rotary evaporation, and MTBE (methyl tert-butyl ether) is added to the concentrated solution to precipitate a white solid, the desired product.

[0039] In some embodiments, the scheme for synthesizing the main chain in step B is the same as the scheme for synthesizing the main chain in step A.

[0040] In some embodiments, the solid phase method in step B is to sequentially couple each branched module with the peptide resin as follows:

[0041] This step is carried out by solid phase synthesis of the polypeptide, and the modular structures of the side chains of the present invention are sequentially and in reverse order connected to the polypeptide main chain on the resin.

[0042] The specific implementation steps are:

[0043] Tetrakis(triphenylphosphine)palladium and PhSiH3 are used to remove the Alloc protection of the main peptide chain X1 (Lys); 3,6-dioxa-octanedioic acid (B2) is pre-activated with a condensation reagent and then reacted and coupled with the main peptide chain for loading; then Fmoc-monoprotected 3,6-dioxa-1,8-octanediamine is added for condensation coupling; Pip / DMF solution or other alkaline solution is used to remove the Fmoc protection; Fmoc-Glu-OtBu is pre-activated with a condensation reagent and then condensed and coupled; Pip / DMF solution or other alkaline solution is used to remove the Fmoc protection; a long fatty diacid mono-protected with the tBu group is condensed and coupled to the α-amino position of Glu; thus completing the loading and synthesis of the entire side chain.

[0044] Optionally, further comprising:

[0045] Chromatographic purification: multi-step reverse phase chromatography purification or ion chromatography purification, and finally salt conversion into an aqueous solution containing the active ingredient; and freeze drying.

[0046] The preparation methods or schemes disclosed herein for the long-acting GLP-1 polypeptide derivatives utilize chemical synthesis. However, according to existing technical approaches, such compounds can be constructed using a semi-synthetic approach combining gene expression and recombination with chemical synthesis. All of these possible implementations are intended to be within the scope of the present invention.

[0047] The present invention discloses a pharmaceutical composition comprising the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient or a main active ingredient, and a pharmaceutically acceptable carrier.

[0048] Pharmaceutically acceptable salts are included as part of the present invention. Suitable "pharmaceutically acceptable salts" include the free compounds of the present invention, conventional non-toxic salts of the compounds of the present invention formed by reaction with inorganic or organic acids, and conventional non-toxic salts of the compounds of the present invention formed by reaction with inorganic or organic bases. For example, these include salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and nitric acid, as well as salts derived from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, and trifluoroacetic acid. For another example, these include salts derived from inorganic bases such as sodium, potassium, calcium, magnesium, zinc, and iron, as well as salts derived from organic bases such as ammonia, arginine, lysine, citrulline, and histidine.

[0049] One of the objectives of the present invention is to develop a clinically viable pharmaceutical formulation based on the GLP-1 polypeptide derivatives of the present invention. Such formulations may further comprise a buffer, preservative, isotonicity agent, solubilizer, tonicity agent, chelating agent, stabilizer, antioxidant, surfactant, acid-base modifier, etc. The concentration is typically 0.01 mg / ml to 50 mg / ml, with the formulation having a pH of 3.0 to 9.0.

[0050] In one embodiment of the invention, the pharmaceutical formulation is an aqueous formulation, ie an aqueous solution, typically a solution, emulsion or suspension.

[0051] In another embodiment, the pharmaceutical preparation is a lyophilized preparation, and a solvent and / or diluent is added thereto to fully dissolve the preparation before use.

[0052] In another embodiment, the pharmaceutical preparation is a ready-to-use dry preparation that does not require pre-dissolution, such as a lyophilized powder for spray inhalation.

[0053] In another embodiment of the present invention, the pH range of the pharmaceutical formulation is critical, as it affects the solubility and stability of the GLP-1 polypeptide derivative and may cause physical aggregation or adsorption of the polypeptide under certain conditions. In one embodiment of the present invention, the pH of the pharmaceutical formulation is 3.0-5.0. In one embodiment of the present invention, the pH of the pharmaceutical formulation is 7.0-8.0. In one embodiment of the present invention, the pH of the pharmaceutical formulation is 7.5-8.5. In another embodiment of the present invention, the pH of the pharmaceutical formulation is 5.0-7.5.

[0054] In a further embodiment of the present invention, the buffer is selected from disodium hydrogen phosphate, sodium acetate, etc., the preservative is selected from phenol, o-cresol, m-cresol, p-cresol, etc., the isotonic agent is selected from sodium chloride salts, sugars or sugar alcohols, amino acids, propylene glycol, mannitol, etc., the solubilizer is selected from mannitol, propylene glycol, PEG, glycerol, Tween, ethanol, etc., the tonicity agent is selected from sodium chloride salts, propylene glycol, glycerol, mannitol, etc., the chelating agent is selected from EDTA, citrate, etc., the stabilizer is selected from creatinine, glycine, nicotinamide, PEG, etc., the antioxidant is selected from sodium bisulfite, sodium sulfite, cysteine, methionine, etc., the surfactant is selected from polysorbate, glycerol, mannitol, etc., and the acid-base regulator is selected from hydrochloric acid, phosphoric acid, sulfuric acid, sodium hydroxide, potassium hydroxide, etc.

[0055] Other ingredients may be present in the pharmaceutical preparation of the GLP-1 polypeptide derivative of the present invention according to the requirements of the pharmaceutical preparation (e.g., long-term stability), including emulsifiers, metal ions, oily carriers, proteins (such as human serum albumin, gelatin or protein, etc.), zwitterions (such as arginine, glycine, lysine, histidine, betaine and taurine, etc.), and other pharmaceutical preparation additives.

[0056] The term "pharmaceutically acceptable carrier" refers to any formulation carrier or medium that can deliver an effective amount of the active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects on the host or patient. Representative carriers include water, oil, liposomes, etc.

[0057] With respect to drugs or pharmacologically active agents, the term "effective amount" or "therapeutically effective amount" refers to a non-toxic but sufficient amount of the drug or agent to achieve the desired effect.

[0058] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating a target disorder, disease, or condition.

[0059] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0060] In a third aspect, the present invention provides the use of the above-mentioned long-acting glucagon-like peptide-1 derivative as a GLP-1 receptor agonist, and the clinical use includes but is not limited to use in the preparation of a medicament for treating or preventing at least one of the following diseases, the diseases including type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, metabolic syndrome, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), etc.

[0061] The pharmaceutically acceptable free compounds or salts of the long-acting glucagon-like peptide-1 derivatives of the present invention can be used to treat diabetes, obesity-related diseases, diabetes-related diseases, and metabolic syndrome. Diabetes mellitus comprises a group of metabolic diseases characterized by hyperglycemia caused by defects in insulin secretion, insulin action, or both. Based on the underlying mechanism, diabetes is categorized into type 1 diabetes, type 2 diabetes, and gestational diabetes.

[0062] Preferably, the invention also includes the use in the preparation of drugs for delaying the efficacy of treatment of type II diabetes and / or preventing the deterioration of type II diabetes, as well as methods for improving blood sugar control in adults with type II diabetes, comprising administering an effective amount of the above-mentioned polypeptide derivatives to patients in need as a diet and exercise supplement.

[0063] Preferably, the invention also includes the use in preparing drugs for delaying the efficacy of treating type II diabetes and / or preventing the deterioration of type II diabetes.

[0064] Preferably, the invention also includes the use in the preparation of drugs for reducing food intake, reducing β-cell apoptosis, increasing pancreatic β-cell function, increasing β-cell mass and / or restoring glucose sensitivity to β-cells.

[0065] The pharmaceutically acceptable free compounds or salts of the long-acting glucagon-like peptide-1 derivatives of the present invention can also be used to treat obesity, insulin resistance, impaired glucose tolerance, prediabetes, elevated fasting blood glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), atherosclerosis, arteriosclerosis, coronary heart disease, peripheral arterial disease, and stroke. These are all conditions that may be associated with obesity. However, the effects of the compounds used in the present invention on these conditions may be mediated in whole or in part by, or independent of, their effects on body weight.

[0066] In certain embodiments, the pharmaceutically acceptable free compound or salt of the GLP-1 receptor agonist polypeptide derivative of the present invention can play a therapeutic role in obesity-related diseases such as obesity-related inflammation, obesity-related gallbladder disease, and obesity-induced sleep apnea.

[0067] The pharmaceutically acceptable free compounds or salts of the GLP-1 receptor agonist polypeptide derivatives of the present invention have positive preventive and therapeutic significance for NAFLD and NASH, which are related to multiple metabolism-related factors and have complex pathogenesis. Insulin resistance and fat metabolism disorders constitute early damage to the liver, thereby forming fat accumulation (NAFLD) in liver cells. As the disease progresses, the body's immune regulation is formed, and liver cells produce an inflammatory response, which then promotes the formation of fibrosis, and ultimately leads to end-stage liver disease symptoms such as cirrhosis. The GLP-1 receptor agonist polypeptide derivatives of the present invention can effectively regulate blood sugar levels and participate in metabolism, and can fully or partially mediate NASH, or can be independent of the above effects.

[0068] The pharmaceutically acceptable free compounds or salts of the GLP-1 receptor agonist polypeptide derivatives of the present invention have positive preventive and therapeutic significance for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), which are related to multiple metabolic factors and have complex pathogenesis.

[0069] Preferably, it also includes reducing the deposition of beta-amyloid plaques in the brain, reducing nerve cell damage caused by oxidative stress, regulating the transmission of synapses, increasing synaptic plasticity, stimulating axonal ropes, affecting long-term potentiation, thereby improving memory and enhancing cognitive levels.

[0070] Preferably, it also includes activating the brain's GLP-1 receptors, enhancing the function of dopamine connections, exerting anti-inflammatory effects, improving energy production and turning on cell survival signals to improve athletic performance.

[0071] Fourthly, the present invention has found that the polypeptide derivative has good long-term effect in vivo, and surprisingly found that the structure of the polypeptide derivative of the present invention has significantly better pharmacokinetic effect due to its difference from existing similar technologies, and has better medicinal potential in terms of indicators such as Cmax and AUC. In particular, in one embodiment, the replacement of eicosanedioic acid greatly prolongs the half-life (almost twice), which is obviously better than the value in relevant literature, and is reflected to a certain extent in the pharmacological content.

[0072] Fifthly, in existing GLP-1 research literature, slight changes in the branching structure often lead to decreased activity or poorer pharmacokinetic results. The present invention surprisingly found that despite changes in the branching structure (and conservative amino acid substitutions in the peptide chain), the polypeptide derivative still has considerable GLP-1 receptor agonist activity, achieving similar or better GLP-1 receptor agonist effects and other therapeutic benefits as semaglutide.

[0073] The term "conservative amino acid substitution" refers to the mutual substitution between aromatic amino acids Phe, Trp, and Tyr under known technical conditions; the mutual substitution between hydrophobic amino acids Leu, Ile, and Val; the mutual substitution between polar amino acids Gln and Asn; the mutual substitution between basic amino acids Lys, Arg, and His; the mutual substitution between acidic amino acids Asp and Glu; and the mutual substitution between hydroxyl amino acids Ser and Thr. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] Figure 1 shows the blood drug concentration-time curve of SD rats after a single dose.

[0075] Figure 2 shows the changes in blood TC levels in ob / ob mice during the hypoglycemic, weight-loss and lipid-lowering experiments.

[0076] Figure 3 shows the changes in blood TG levels in ob / ob mice after hypoglycemic, weight-loss and lipid-lowering experiments.

[0077] Figure 4 shows the changes in blood LDL-c levels in ob / ob mice after hypoglycemic, weight-loss and lipid-lowering experiments.

[0078] Figure 5 shows the changes in blood HDL-c levels in ob / ob mice during the hypoglycemic, weight-loss and lipid-lowering experiments.

[0079] Figure 6 shows the changes in blood TC levels in DIO mice during the hypoglycemic, weight-loss and lipid-lowering experiments.

[0080] Figure 7 shows the changes in blood TG levels in DIO mice after hypoglycemic, weight loss and lipid-lowering experiments.

[0081] Figure 8 shows the changes in blood LDL-c levels in DIO mice during the hypoglycemic, weight-loss and lipid-lowering experiments.

[0082] FIG9 shows the changes in blood HDL-c levels in DIO mice during the hypoglycemic, weight loss and lipid-lowering experiments. DETAILED DESCRIPTION

[0083] The following examples may enable those skilled in the art to more fully understand the present invention, but should not limit the present invention in any way.

[0084] Example 1: Preparation of polypeptide compound (3)

[0085] ESI-MS: [M+5H]818.16, [M+4H]1021.43, [M+3H]1362.88.

[0086] 1) Liquid phase synthesis of branched fragments

[0087] 3,6-dioxane-1,8-octanedioic acid monoprotected with benzyl ester was coupled with 3,6-dioxane-1,8-octanediamine monoprotected with Boc (tert-butyloxycarbonyl) using EDC+HOBt condensation under N-methylmorpholine conditions, and the Boc protection was removed with 33% TFA / DCM solution; Fmoc-Glu-OtBu was coupled with the product of the previous step using DCC+HOSu condensation, and the Fmoc protection was removed with 50% morpholine / DCM solution; octadecane dioic acid monoprotected with tBu group was condensed and coupled to the amino position of Glu; finally, the benzyl ester was removed by hydrogen hydrolysis under the catalysis of palladium on carbon.

[0088] 2) Solid-phase synthesis of peptide chains

[0089] Fmoc-protected amino acids were sequentially coupled to a solid-phase synthesis resin according to the amino acid sequence of the molecular structure. Rink Acid resin was used as the solid-phase synthesis support. Fmoc was deprotected with 50% piperazine / DCM solution, and this cycle was repeated until all the amino acids in the peptide chain were complete. The Lys-protected amino acid of the branched segment to be connected was prepared using the raw material Fmoc-Lys(Alloc)-OH, and the α-amino group of the final amino acid, His, was protected with a Boc group.

[0090] 3) Coupling the branched fragment to the peptide resin

[0091] Tetrakis(triphenylphosphine)palladium and PhSiH3 were used to remove the Alloc protection of Lys on the peptide chain; the branched fragments were condensed and coupled to the peptide resin using TBTU / DIEA; 50% piperazine / DCM solution was used to remove the Fmoc protection;

[0092] 4) Cleavage to remove protecting groups and resin mounting

[0093] Prepare a cleavage solution in the ratio of (TFA:EDT:TIS:H2O=95:2:2:1) and add the fully protected peptide resin to the cleavage solution to cleave it from the resin and remove the side chains. Remove the TFA by vacuum rotary evaporation and add petroleum ether to the concentrated solution to precipitate a white solid, the target product.

[0094] 5) Chromatographic purification and freeze-drying

[0095] The purification is carried out by combining ion chromatography and reverse phase chromatography, and finally the salt is converted into a sodium-containing aqueous solution and freeze-dried.

[0096] Example 2 Preparation of polypeptide compound (1)

[0097] ESI-MS: [M+5H]823.75, [M+4H]1029.43, [M+3H]1372.25

[0098] 1) Solid phase synthesis of branched fragments;

[0099] 3,6-Dioxa-octanedioic acid was dissolved in DCM and mounted on 2-CTC resin under the catalysis of DIEA; Fmoc-3,6-dioxa-1,8-octanediamine was coupled to the resin using HATU / DIEA; Fmoc protection was removed with 15% Pip / DMF solution; Fmoc-Glu-OtBu was condensed onto the resin using PyBoP / DIEA; Fmoc protection was removed with 15% Pip / DMF solution; finally, tBu group-monoprotected octadecane dioic acid was condensed and coupled to the amino position of Glu; 30% TFE / DCM cleavage was performed to obtain a branched fragment intermediate.

[0100] 2) Solid phase synthesis of peptide chains;

[0101] Fmoc-protected amino acids were sequentially coupled to a solid-phase synthesis resin according to the amino acid sequence of the molecular structure. Wang resin was used as the solid-phase synthesis support. 15% PIP / DMF solution was used to deprotect the Fmoc residues, and this cycle was repeated until all the amino acids in the peptide chain were complete. The Lys-protected amino acid of the branched segment to be connected was prepared using the raw material Fmoc-Lys(Alloc)-OH, and the α-amino group of the last amino acid, His, was protected with a Boc group.

[0102] 3) coupling the branched fragment to the peptide resin;

[0103] Tetrakis(triphenylphosphine)palladium and PhSiH3 were used to remove the Alloc protection of Lys on the peptide chain; the branched fragment intermediate was condensed onto the peptide resin using HATU / DIEA coupling.

[0104] 4) Cleavage and removal of the protecting group and the resin mounting to obtain a long-acting glucagon-like peptide-1 derivative.

[0105] A cleavage buffer was prepared in the ratio of (TFA:phenol:TIS:H2O=95:2:2:1). The fully protected peptide resin was added to the cleavage buffer to cleave it from the resin and remove the side chains. TFA was removed by vacuum rotary evaporation. Ether was added to the concentrate to precipitate an off-white solid, the target product. Purification was performed using a combination of ion chromatography and reversed-phase chromatography. Finally, the free peptide compound solution was converted to a salt and lyophilized.

[0106] Example 3 Preparation of polypeptide compound (4)

[0107] ESI-MS: [M+4H]1029.48, [M+3H]1372.26.

[0108] 1) Solid phase synthesis of peptide chains;

[0109] Fmoc-protected amino acids were sequentially coupled to a solid-phase synthesis resin according to the amino acid sequence of the molecular structure. Rink Acid resin was used as the solid-phase synthesis support, and Fmoc protection was removed using a 50% ethanolamine / DCM solution. TBTU / DIEA was used as the condensation reagent, and the reaction cycle was repeated until all the amino acids in the peptide chain were complete. The Lys-protected amino acid of the branched segment to be connected was protected with the raw material Fmoc-Lys(Dde)-OH, and the α-amino group of the final amino acid, His, was protected with a Boc group.

[0110] 2) The side chain modules are coupled to the peptide resin one by one using the solid phase method;

[0111] 2% hydrazine hydrate / DMF was used to remove the Dde protection of the main peptide chain X1 (Lys); 3,6-dioxa-octanedioic acid (B2) was pre-activated with a condensation reagent and then reacted and coupled with the main peptide chain for loading; then Fmoc-monoprotected 3,6-dioxa-1,8-octanediamine was added for condensation coupling; 50% ethanolamine / DCM solution was used to remove the Fmoc protection; condensation reagent TBTU / DIEA was used to pre-activate Fmoc-Glu-OtBu, and then condensed and coupled to the peptide resin; 50% ethanolamine / DCM solution was used to remove the Fmoc protection; tBu group-monoprotected octadecane dioic acid was condensed and coupled to the α-amino position of Glu; thus completing the loading and synthesis of each module of the entire side chain.

[0112] 3) Cleavage and removal of the protecting group and the resin mounting to obtain a long-acting glucagon-like peptide-1 derivative.

[0113] The cleavage process was similar to that of Example 1, with isopropyl ether crystallization used during cleavage. Purification was performed by combining ion chromatography and reverse phase chromatography, and finally the product was converted into a trifluoroacetate solution and freeze-dried.

[0114] Example 4 Pharmacokinetics of single-dose administration in SD rats

[0115] SD rats, both male and female, were randomly numbered and divided into groups, with n≥6 animals in each group.

[0116] Preparation method of test solution: Take an appropriate amount of test drug and fully dissolve it with water for injection to obtain a test solution with a concentration of 0.09 mg / mL. Prepare it before administration and store it at 2-8°C.

[0117] The dose was 0.18 mg / kg in a 2.0 mL / kg dosing volume. Administration was via subcutaneous injection into the back. Blood (0.1 mL) was collected from the eye socket before dosing and at 0.5, 2.5, 5.5, 7.0, 8.0, 9.0, 10.0, 12.0, 16.0, 24.0, 32.0, and 48.0 hours after dosing. The blood was placed in an EDTA-K2 anticoagulant tube in an ice bath. Within 2 hours, the blood was centrifuged at 5000 rpm for 10 minutes at 4°C. Plasma was collected and temporarily stored on dry ice. It was then refrigerated below -60°C within 14 hours. Plasma samples were analyzed using an established LC-MS / MS method.

[0118] The original data obtained from the experiment were fitted by the instrument software to obtain the standard curve equation and correlation coefficient, and the drug concentration in the plasma samples at each sampling time point and the concentration of the accompanying quality control samples were calculated.

[0119] Raw data were statistically analyzed using SPSS 21.0. Drug concentration and time data were used to calculate metabolic kinetic parameters using WinNonlin 6.4 software according to the non-compartmental model. The pharmacokinetic results are shown in Table 1 and Figure 1.

[0120] Table 1: Results of single-dose pharmacokinetic experiments in SD rats

[0121] The experimental results show that, compared with the positive control drug semaglutide, under the same dosage conditions, the Cmax and AUC of the compounds of the present invention (1), (3), and (4) are significantly higher than those of the positive control. This means that in the study of drug exposure-effect relationship, the compounds of the present invention only need a lower or smaller dose to achieve or reach the drug effect, thereby better ensuring the safety and efficacy of the drug. In addition, the half-life of the compound of the present invention (4) is significantly prolonged by almost one-fold, and its long-term effect is extremely significant, providing a guarantee for reducing the number of drug administrations and improving patient compliance in the future clinical practice.

[0122] Example 9 Experiment on reducing blood sugar, weight and lipid in ob / ob mice

[0123] Thirty-two ob / ob mice were randomly divided into four groups based on their fasting body weight, fasting serum TC, and LDL-c, namely, model control group, peptide compound (3) group, peptide compound (4) group, and semaglutide group, with 8 mice in each group. Another 8 mice fed a conventional diet were set up as the normal control group (vehicle).

[0124] The drug was administered subcutaneously once every 3 days (except the compound (4) group), for a total of 8 times (D0, D3, D6, D9, D12, D15, D18, and D21); the compound (4) group was administered subcutaneously once every 4 days, for a total of 6 times (D0, D4, D8, D12, D16, and D20). The model control group and the normal control group were given normal saline (0.15 mL / 20 g), and the test polypeptide compound (3) group, polypeptide compound (4) group, and semaglutide group were all administered at a dose of 0.312 mg / kg.

[0125] (1) Body weight: Body weight was measured once every 12 hours before grouping, with or without food or water. The subjects were randomly divided into groups based on body weight, TC, and LDL balance. After grouping, body weight was measured once a day starting from D0.

[0126] (2) Lee's Index: Body length was measured before the first administration and on D23. Body length was the maximum straight-line distance from the nose tip to the anus. The mouse was positioned so that its body was in a stretched state, and the body length was read using a ruler.

[0127] Lee's index = [body weight (g) × 10 3 / Body length (cm)] 1 / 3 .

[0128] (3) Determination of blood glucose (GLU): Measure once every 3 days.

[0129] (4) Blood biochemistry (TG, TC, LDL-c, HDL-c): measured before grouping, on D11 and D23 respectively.

[0130] (5) Fat-to-body weight coefficient: After euthanasia of mice, abdominal subcutaneous fat, perigonadal fat, and scapular subcutaneous fat were removed and weighed separately to calculate the fat-to-body weight coefficient.

[0131] The experimental results are as follows:

[0132] (1) Weight:

[0133] During the experiment, the animals in the model control group gained weight the fastest, and their average weight was significantly higher than that of the normal control group (p<0.01). During the experiment, the animals in the normal control group gained an average of 7.1g, the animals in the model control group gained an average of 12.4g, the animals in the polypeptide compound (4) group gained an average of 4.8g, the animals in the polypeptide compound (3) group gained an average of 5.6g, and the animals in the semaglutide group gained an average of 6.5g.

[0134] Starting from D1, the weight of the animals in the polypeptide compound (4), polypeptide compound (3) and semaglutide groups decreased, and the weight gain was slow during the experimental period (D1-D23), which was significantly lower than that of the model control group (p < 0.01). The average weight of the polypeptide compound (4) and (3) groups was lower than that of the semaglutide group. Although there was no statistical difference, it showed that certain pharmacokinetic advantages had an effect on drug efficacy. Specific results are shown in Table 2.

[0135] Table 2: Body weight of experimental animals in ob / ob mice experiment Note: Compared with the model control group, *p<0.05, **p<0.01; compared with the positive drug, #p<0.05, ##p<0.01.

[0136] (2) Lee's Index

[0137] The Lee's Index, a useful indicator of obesity in mice, increased in all animals, with the smallest increase seen in the normal control group. Compared with the model control group, the Lee's Index in all treatment groups decreased slightly, demonstrating statistically significant differences. These results demonstrate that both the test drug and the positive drug have an inhibitory effect on obesity in ob / ob mice, with similar control abilities between the test and positive drug groups, with no statistically significant difference. See Table 3 for detailed results.

[0138] Table 3: Lee's Index results of ob / ob mouse experiments Note: Compared with the model control group, *p<0.05, **p<0.01; compared with the positive drug, #p<0.05, ##p<0.01.

[0139] (3) Random blood glucose:

[0140] During the experiment, the random blood glucose concentration of the animals gradually increased, which may be related to their age and weight gain. Compared with the model control group, the blood glucose values ​​of the normal control group animals on D14-D23 were significantly lower than those of the model control group mice, indicating that the basal blood glucose values ​​of ob / ob mice were higher. Compared with the model control group mice, the D3-D23 peptide compound (3) and the peptide compound (4) had different degrees of significant hypoglycemic effects with the positive drug, and most of them had significant differences. There was no significant difference between the peptide compound (3) and the peptide compound (4) and semaglutide. The specific results are shown in Table 4 (unit: mmol / L).

[0141] Table 4: Random blood glucose changes in ob / ob mice Note: Compared with the model control group, *p<0.05, **p<0.01; compared with the positive drug, #p<0.05, ##p<0.01.

[0142] (4) Blood biochemistry

[0143] (a) TC: Before administration (D0), the initial TC levels of the animals in each group were relatively similar. At D11 and D23 after administration, compared with the model control group, the peptide compound (3) and peptide compound (4) groups significantly reduced TC levels (p < 0.05), and their ability to reduce TC was significantly better than that of semaglutide. Although the semaglutide group showed a decrease in TC levels compared with the model group, there was no statistical difference. Specific results are shown in Figure 2.

[0144] (b) TG: Before administration (D0), the TG levels of mice of the same strain were relatively close. During the experiment, the TG levels of mice in the model control group were higher than those in the normal control group. On D11 after administration, polypeptide compound (4) could significantly reduce TG levels (p<0.05), and its effect was significantly better than that of the semaglutide group. Similarly, polypeptide compound (3) could also significantly reduce TG levels, but there was no statistical difference compared with the semaglutide group. On D23 after administration, compared with the model control group, the polypeptide compound (3) group, the polypeptide compound (4) group and the semaglutide group could all reduce TG levels, but there was no statistical difference. The specific results are shown in Figure 3.

[0145] (c) LDL-c: Before administration (D0), the TG levels of mice of the same strain were relatively similar. On D11 after administration, compared with the model control group, the polypeptide compound (3) and polypeptide compound (4) groups and semaglutide could significantly reduce the LDL-c level (p < 0.01). On D23 after administration, the polypeptide compound (3) and polypeptide compound (4) groups were more effective in reducing LDL-c than the semaglutide group (p < 0.05), while there was no statistical difference between the semaglutide group and the model control group. The specific results are shown in Figure 4.

[0146] (d) HDL-c: Before administration (D0), the HDL levels of mice of the same strain were relatively similar. During the experiment, the HDL levels of mice in the model control group were higher than those in the normal control group. Compared with the model control group, on D11 and D23 after administration, the HDL levels of each test group and the positive drug group were significantly reduced (p<0.05). However, the values ​​of the polypeptide compound (3) and polypeptide compound (4) groups were lower than those of the positive drug group. Because HDL has an "anti-atherosclerotic" effect, a lower value means that the polypeptide compound (3) and polypeptide compound (4) groups are not as good as the positive drug group in terms of HDL. Specific results are shown in Figure 5.

[0147] (5) Fat-weight coefficient

[0148] After 23 days of administration, the mice were dissected, fat in different parts of the body was separated, and the fat-to-body weight coefficient was calculated according to the formula (fat / body weight × 100). The results show that the fat-to-body weight coefficients of the model control group mice were significantly higher than those of the normal control group mice. The test drugs, polypeptide compound (1) and polypeptide compound (3), can significantly reduce the subcutaneous fat and perigonadal fat in the abdomen of ob / ob mice, and the effect is not statistically significantly different from that of the positive drug semaglutide. In addition, the drug has no effect on the subcutaneous fat-to-body weight coefficient of the scapula. The specific results are shown in Table 5.

[0149] Table 5: Results of the fat-to-body weight coefficient experiment on ob / ob mice Note: Compared with the model control group, **p<0.01

[0150] Comprehensive analysis of the above experimental data shows that the polypeptide derivatives (3) and (4) of the present invention have quite good GLP-1 receptor agonist activity, achieving a GLP-1 receptor agonist effect similar to or better than that of the positive control drug semaglutide, achieving fat-reducing and blood sugar-lowering effects in ob / ob model mice, and having better therapeutic benefits in terms of certain indicators of blood lipids.

[0151] Example 10 Experiment on hypoglycemic, weight-reducing and lipid-lowering in DIO mice

[0152] Thirty-two DIO male mice were randomly divided into four groups based on their fasting body weight and fasting serum TC and LDL-c levels before administration, namely the model control group, the polypeptide compound (2) group, the polypeptide compound (4) group, and the semaglutide group, with 8 mice in each group. In addition, 8 C57BL / 6J male mice fed with conventional diet were set as the normal control group.

[0153] The semaglutide group was administered subcutaneously once every 3 days, for a total of 8 doses (D0, D3, D6, D9, D12, D15, D18, and D21), with a dose of 0.312 mg / kg; the compound (2) group and the compound (4) group were administered subcutaneously once every 4 days, for a total of 6 doses (D0, D4, D8, D12, D16, and D20), with a dose of 0.312 mg / kg; the model control group and the normal control group were administered subcutaneously once every 4 days, for a total of 6 doses (D0, D4, D8, D12, D16, and D20), with a dose of 0.15 mL / 20 g.

[0154] (1) Body weight: Body weight was measured once every 12 hours before grouping, after fasting but not drinking water. Subjects were randomly divided into groups based on their body weight, TC, and LDL-c test results. After grouping, body weight was measured once daily starting on D0.

[0155] (2) Lee's Index: Body length was measured before the first administration and on D23. Body length was the maximum straight-line distance from the nose tip to the anus. The mouse was positioned so that its body was in a stretched state, and the body length was read using a ruler.

[0156] Lee's index = [body weight (g) × 10 3 / Body length (cm)] 1 / 3 .

[0157] (3) Determination of blood glucose (GLU): Measure once every 3 days.

[0158] (4) Blood biochemistry (TG, TC, LDL-c, HDL-c) measurements: The measurements were performed before grouping and on D11 and D23 after administration.

[0159] (5) Fat-to-body weight coefficient: After euthanasia on day 23, the subcutaneous fat of the abdomen, perigonal fat, and scapular subcutaneous fat were removed and weighed respectively to calculate the fat-to-body weight coefficient.

[0160] The experimental results are as follows:

[0161] (1)Weight

[0162] The experimental results showed that the model control group had the fastest weight gain, with an average weight gain of 5.04g; the normal control group had an average weight gain of 1.26g; the compound (4) group had an average weight loss of 0.90g, the compound (2) group had an average weight loss of 2.73g; and the semaglutide group had an average weight loss of 1.55g. Due to the fasting procedure, the average weight gain of each group was calculated by subtracting the average weight on D0 from the average weight on D22.

[0163] Compared with the normal control group, the model control group showed a significant increase in body weight in the middle and late stages of the experiment (D16 and D19-23) (p<0.05 or p<0.01); compared with the model control group, the compound (2) group, the compound (4) group and the semaglutide group showed a significant decrease in body weight from the start of administration to the end of the observation period (p<0.05 or p<0.01); compared with the semaglutide group, the compound (2) group and the compound (4) group showed no difference in the overall trend of weight loss, the compound (4) group showed a significantly higher weight loss than the semaglutide group on D6-9 (p<0.05 or p<0.01), and the compound (2) group showed a significantly higher weight loss than the semaglutide group on D9 (p<0.01). The results showed that the compounds (2) and (4) of the present invention had good body weight reduction activity, reaching the level of weight reduction efficacy of the control drug semaglutide, and compound (4) may have a better body weight reduction effect. In addition, the two compounds of the present invention had a longer dosing interval and better compliance. The results are shown in Table 6.

[0164] Table 6: DIO mouse body weight results Note: Compared with the model control group, *p<0.05, **p<0.01; compared with the positive drug, #p<0.05, ##p<0.01.

[0165] (2) Lee's Index

[0166] Before the start of the experiment (D0), there was no statistical difference in the Lee's index of the animals in each group (p>0.05), and the values ​​were close. Compared with D0, on D23, the Lee's index of the mice in all groups except the model control group decreased. Compared with the model control group, the Lee's index of the animals in each drug-treated group on D23 decreased significantly (p<0.01). Compared with the semaglutide group, there was no significant difference in the Lee's index between the polypeptide compound (4) group and the polypeptide compound (2) group (p>0.05). The results showed that polypeptide compound (4), polypeptide compound (2) and semaglutide can significantly reduce the Lee's index of DIO mice, and the three drugs have similar ability to reduce the Lee's index. The results are shown in Table 7.

[0167] Table 7: Lee's Index results of DIO mice Note: Compared with the model control group, *p<0.05, **p<0.01; compared with the positive drug, #p<0.05, ##p<0.01.

[0168] (3) Random blood glucose

[0169] Blood glucose levels of the experimental animals were measured on days 3, 7, 10, 14, 17 and 21 after administration. The results showed that compared with the normal control group, the blood glucose concentration of the model control group was significantly increased on D7, D14 and D21 (p<0.05 or p<0.01), and there was no significant increase at other time points (p>0.05); compared with the model control group, the blood glucose concentrations of the polypeptide compound (4) group, the polypeptide compound (2) group and the semaglutide group decreased to varying degrees on D3-D21, among which the polypeptide compound (4) group decreased significantly on D3, D7, D14 and D21 (p<0.05 or p<0.01), and the polypeptide compound (2) group decreased significantly on D3 , D17 and D21 decreased significantly (p < 0.05 or p < 0.01), and the semaglutide group decreased significantly on D10 and D21 (p < 0.05 or p < 0.01); compared with semaglutide, the blood glucose concentrations of the polypeptide compound (4) group and the polypeptide compound (2) group decreased significantly or increased significantly during the administration period, which may be related to the different administration intervals. However, judging from the observation end point (D21), the blood glucose concentrations of the polypeptide compound (4) group and the polypeptide compound (2) group were significantly lower than those of the semaglutide group (p < 0.05 or p < 0.01). The results show that the polypeptide compound (4) and the polypeptide compound (2) of the present invention controlled the blood glucose concentration of animals well during the administration period, and the hypoglycemic effect at the observation end point (D21) was better than that of semaglutide, and the administration interval was longer, and the compliance was better. The results are shown in Table 8.

[0170] Table 8: Random blood glucose changes in DIO mice Note: Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive drug, #p<0.05, ##p<0.01.

[0171] (4) Blood biochemistry

[0172] (a) TC: Before the experiment (D0), the TC levels of the DIO mice in each group were similar and significantly higher than those in the normal control group (p < 0.01), which may be related to the different feed structures that the animals have been taking for a long time. As the experiment progressed, the TC level of the model control group gradually increased, from (2.68 ± 0.59) mmol / L on D0 to (4.22 ± 0.62) mmol / L on D23. After administration, it was clearly observed that the TC levels of the mice in each group decreased. Compared with the model control group, the TC content of the polypeptide compound (4) group, the polypeptide compound (2) group and the semaglutide group decreased significantly on D11 and D23 (p < 0.01). Except for D11, the effect of polypeptide compound (4) on reducing TC was weaker than that of semaglutide (p < 0.05). There was no significant difference between polypeptide compound (4), polypeptide compound (2) and the positive drug semaglutide. The results showed that the polypeptide compound (4) and the polypeptide compound (2) of the present invention had a good effect in reducing the TC content in the blood, and their reduction of TC activity in the blood was similar to that of the positive control drug semaglutide. The specific results are shown in Figure 6.

[0173] (b) TG: Before the start of the experiment (D0), the TG levels of the DIO mice in each group were similar and showed no significant difference from those in the normal control group (p>0.05). As the experiment progressed, the TG level of the model control group gradually increased, from (0.63±0.24) mmol / L on D0 to (1.55±0.41) mmol / L on D23. The TG levels of the other DIO-administered groups of mice also increased slightly as the experiment progressed. Compared with the model control group, the serum TG levels of the peptide compound (4) group, the peptide compound (2) group, and the semaglutide group were significantly reduced on D11 and D23 (p<0.05 or p<0.01). Compared with semaglutide, the peptide compound (4) group and the peptide compound (2) group had weaker effects on reducing TG than semaglutide on D11 and D23 (p<0.05 or p<0.01). The results showed that the polypeptide compound (4) and the polypeptide compound (2) of the present invention have the ability to reduce TG activity, and the activity of both compounds is weaker than that of the positive control drug semaglutide. Specific results are shown in Figure 7.

[0174] (c) LDL-c: Before the experiment (D0), the LDL-c levels of the DIO mice in each group were similar and significantly lower than those of the normal control group (p < 0.05), which may be related to the different feed structures that the animals have been taking for a long time. As the experiment progressed, the LDL-c level of the model control group gradually increased, from (1.23 ± 0.21) mmol / L on D0 to (2.56 ± 0.67) mmol / L on D23. The LDL-c levels of the other DIO-administered groups of mice also increased slightly as the experiment progressed. Compared with the model control group, the LDL-c levels in the serum of the peptide compound (4) group, the peptide compound (2) group, and the semaglutide group were significantly reduced on D11 and D23 (p < 0.05 or p < 0.01). Compared with the semaglutide group, the effect of polypeptide compound (4) in lowering LDL-c at D11 and D23 was not significantly different (p>0.05), while the effect of polypeptide compound (2) was weaker than that of semaglutide (p<0.01). The results showed that polypeptide compound (4) and polypeptide compound (2) of the present invention have the activity of lowering LDL-c. The activity of polypeptide compound (4) is similar to that of the positive control drug semaglutide, while the activity of polypeptide compound (2) is weaker than that of the positive control drug semaglutide. The specific results are shown in Figure 8.

[0175] (d) HDL-c: Before the experiment (D0), the HDL-c levels of the DIO mice in each group were similar and had no significant difference with the normal control group (p>0.05). As the experiment progressed, the serum HDL-c levels of the mice in each group increased, with similar increasing trends. Compared with the model control group, the HDL-c content in the serum of the polypeptide compound (4) group was significantly reduced on D23 (p<0.01), the HDL-c content in the serum of the polypeptide compound (2) group was significantly increased on D23 (p<0.05), and the HDL-c content in the serum of the semaglutide group was significantly higher on D11 and D23 (p<0.05 or p<0.01); compared with the semaglutide group, the HDL-c content in the serum of the polypeptide compound (4) group was significantly reduced on D11 and D23 (p<0.01), and the HDL-c content in the serum of the polypeptide compound (2) group was not significantly different on D11 and D23 (p>0.05). The results showed that both peptide compound (2) and semaglutide could increase serum HDL-c levels in DIO mice, while peptide compound (4) actually decreased HDL levels in this experiment. Specific results are shown in Figure 9.

[0176] (5) Fat-weight coefficient

[0177] After 23 days of administration, the mice were dissected, fat in different parts of the body was separated, and the fat-to-body weight coefficient was calculated according to the formula (fat / body weight × 100). The results showed that the fat-to-body weight coefficients of the model control group mice in the subcutaneous abdomen, around the gonads, and subcutaneous scapula were significantly higher than those of the normal control group mice (p < 0.01), indicating that the fat content in the mice fed with a long-term high-fat diet was high. The test drugs, polypeptide compound (4), polypeptide compound (2), and semaglutide, could significantly reduce the fat in the subcutaneous abdomen, around the gonads, and subcutaneous back of DIO mice (p < 0.01). There was no significant difference between the polypeptide compound (4) group and the polypeptide compound (2) group and semaglutide in reducing the fat-to-body weight coefficient (p > 0.05). The results are shown in Table 9.

[0178] Table 9: Fat-to-body weight coefficient results for DIO mice Note: **p<0.01 compared with the model control group.

[0179] Comprehensive analysis of the above experimental data shows that the polypeptide derivatives (2) and (4) of the present invention have quite good GLP-1 receptor agonist activity, achieving a GLP-1 receptor agonist effect similar to or better than that of the positive control drug semaglutide, and achieving fat-reducing and blood sugar-lowering effects in DIO model mice.

Claims

1. A long-acting glucagon-like peptide-1 derivative or a pharmaceutically acceptable salt thereof, wherein the long-acting glucagon-like peptide-1 derivative is represented by formula (I), and X1 in the main chain has only one amino group of its side chain connected to the acyl group of the side chain represented by formula (II) to form an amide: in, Aib is aminoisobutyric acid, X1 is selected from K amino acid, X2 is selected from K or R amino acid, X1 has only one amino group on its side chain connected to the acyl group of the branch shown in formula (II) to form an amide; n is 7 or 8.

2. The polypeptide derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that The polypeptide main chain has only Lys at position X1, and its side chain ε-amino group is connected to the side chain containing long fatty acid, PEG linker and glutamic acid modification in the form of amide bond.

3. The long-acting glucagon-like peptide-1 derivative according to claim 1, characterized in that The long-acting glucagon-like peptide-1 derivative is shown in formula (III):

4. The long-acting glucagon-like peptide-1 derivative according to claim 1, characterized in that The long-acting glucagon-like peptide-1 derivative is shown in formula (IV):

5. The long-acting glucagon-like peptide-1 derivative according to claim 1, characterized in that: The long-acting glucagon-like peptide-1 derivative is shown in formula (V):

6. The long-acting glucagon-like peptide-1 derivative according to claim 1, characterized in that: The long-acting glucagon-like peptide-1 derivative is shown in formula (VI):

7. The method for preparing the long-acting glucagon-1 derivative according to any one of claims 1 to 6, characterized in that: The method includes the following steps A: 1) Synthesis of branched fragments by solid or liquid phase method; 2) Solid phase method for peptide chain synthesis; 3) coupling the branched fragment to the peptide resin; 4) Cleavage and removal of the protecting group and the resin mounting to obtain a long-acting glucagon-like peptide-1 derivative. Or include the following step B: 1) Solid phase method for peptide chain synthesis; 2) The solid phase method is used to couple each branch chain module to the peptide resin one by one; 3) Cleavage and removal of the protecting group and the resin mounting to obtain a long-acting glucagon-like peptide-1 derivative.

8. A pharmaceutical composition, characterized in that The invention comprises the long-acting glucagon-like peptide-1 derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition according to claim 8, characterized in that The pharmaceutically acceptable salt is a free compound of the long-acting glucagon-like peptide-1 derivative, or a salt formed by reaction with an inorganic acid or an organic acid, or a salt formed by reaction with an inorganic base or an organic base; preferably a salt formed with an inorganic acid, and more preferably a salt formed with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or nitric acid; or preferably a salt formed with an organic acid, and more preferably a salt formed with acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, or trifluoroacetic acid; preferably a salt formed with an inorganic base, and more preferably a salt with sodium, potassium, calcium, magnesium, zinc, or iron; or preferably a salt formed with an organic base, and more preferably a salt with ammonia, arginine, lysine, citrulline, or histidine.

10. The pharmaceutical composition according to claim 8, characterized in that The pharmaceutical composition is an aqueous preparation, a lyophilized preparation or a ready-to-use dry preparation, etc. The preparation may contain one or more of a buffer, a preservative, an isotonic agent, a solubilizer, a tonicity agent, a chelating agent, a stabilizer, an antioxidant, a surfactant, an acid-base regulator, an emulsifier, a metal ion, an oily carrier, a protein, a zwitterion, and other pharmaceutical preparation additives.

11. The pharmaceutical composition according to claim 8, characterized in that The concentration of the pharmaceutical composition is usually 0.01 mg / ml to 50 mg / ml, and has a pH value of 3.0 to 9.

0.

12. Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to any one of claims 8 to 11 in the preparation of a medicament for treating and / or preventing at least one of the following diseases: type II diabetes, impaired glucose tolerance, type I diabetes, obesity, metabolic syndrome.

13. Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to any one of claims 8 to 11 in the preparation of a drug for treating delayed drug effect of type II diabetes and / or preventing worsening of type II diabetes.

14. The use according to claim 12, characterized in that Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to any one of claims 8 to 11 in the preparation of a drug for reducing food intake, reducing β-cell apoptosis, increasing pancreatic β-cell function, increasing β-cell mass and / or restoring glucose sensitivity to β-cells.

15. Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to any one of claims 8 to 11 in the preparation of a medicament for treating and / or preventing at least one of the following obesity-related diseases: obesity, insulin resistance, impaired glucose tolerance, prediabetes, elevated fasting blood glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), atherosclerosis, arteriosclerosis, coronary heart disease, peripheral arterial disease and stroke.

16. The use according to claim 15, characterized in that Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to any one of claims 8 to 11 in obesity-related diseases such as obesity-related inflammation, obesity-related gallbladder disease and obesity-induced sleep apnea.

17. Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to any one of claims 8 to 11 in the preparation of a medicament for treating and / or preventing at least one of the following diseases: non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD).

18. The use according to claim 17, characterized in that Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to any one of claims 8 to 11 in diseases related to insulin resistance, fat metabolism disorders, etc.

19. Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 6 or the pharmaceutical composition as described in any one of claims 8 to 11 in the preparation of a medicament for treating and / or preventing at least one of the following diseases: neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), etc.

20. The use according to claim 19, characterized in that Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 6 or the pharmaceutical composition as described in any one of claims 8 to 11 in the preparation of a drug for reducing the deposition of amyloid beta plaques in the brain, reducing nerve cell damage caused by oxidative stress, regulating synaptic transmission, increasing synaptic plasticity, stimulating axonal cords, and affecting long-term potentiation.

21. The use according to claim 19, characterized in that Use of the long-acting glucagon derivative or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 6 or the pharmaceutical composition as described in any one of claims 8 to 11 in the preparation of a drug for activating the GLP-1 receptor in the brain, enhancing the function of dopamine connection, exerting anti-inflammatory effects, improving energy production and turning on cell survival signals.

Citation Information

Patent Citations

  • Acylated GLP-1 compounds

    CN101133082A

  • Glucagon-like protein-1 receptor (GLP-1R) agonist compounds

    CN101663317A

  • Synthesis method of semaglutide

    CN106749613A

  • Synthesis method of acylated GLP-1 compound and modified gene thereof

    CN111378028A

  • Long-acting glucagon-like peptide-1 derivative as well as preparation method and application thereof

    CN116891522A